net dbt
guid confus signal visibl
guid leav question tough answer
cardin result contain number move piec although confus
outlook even signific given manag expect
far current consensu outlook continu get hit number
headwind across segment pharma revenu growth quit strong like
aid growth cah largest custom margin remain pressur
gross oper level addit medic segment continu
hamper cordi turnaround well commod price pressur although
manag remain focus drive stabil perform all-in see
meaning chang on-going concern question busi
ebit guid leav steeper ramp end year
backdrop drug price question januari account
reduct ebit outlook reiter under-perform rate price object
remain unchang stock still remain low end histor rang
see identifi catalyst drive near-term upsid
lower ebit off-set somewhat tax/shar count
follow earn maintain ep reduc
ep reduc ebit segment account
on-going headwind gross margin increment expens off-set
lower tax share count would also note base perform well
outlook guidanc segment profit pharma
medic given multipl uncertainti maintain price object
equat ep estim
upcom event catalyst
given expect pace ebit ramp remaind year key upcom
catalyst anyth give greater clariti ramp includ
manag commentari intra-quart pace growth well brand
price increas shake cours quarter januari
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug medic product
two-third profit pharmaceut
busi nearli one-third medic
support retail/mail/hospital/physician client
well drug manufactur medic busi
manufactur portfolio medic
product distribut brand-nam product
hospit physician compani base
under-perform rate driven increasingli
competit market compani core
busi pharmaceut medic devic
limit near-term offset think market
pharmaceut distribut remain
challeng near term histor upsid driver
red oak sourc benefit slow
medic cordi platform like support
solid growth ex-u see price volum
lower tax rate tax reform discret item
discret item includ primarili continu work allevi tax rate pressur
creat cordi key area
increas revenu due strong specialti solut busi
increas volum relat grow exist custom base
decreas revenu driven divestitur china busi
decreas profit due perform gener program
increas profit due expand offer patient recoveri
growth asia cost demand plan inventori challeng
expect cordi stabil return profit growth end
headwind due divestitur increas cost brand name product
continu six strateg initi cost structur reduct cordi patient
exit china busi navihealth busi partnership
board approv share repurchas program quarterli dividend
expect strong specialti pharmaceut bottom top-line growth
expect oper perform line meet exceed
save goal put forth august
revenu top line pharmaceut segment grew significantli translat
op profit drive averag top line growth flow
revenu growth due strongli grow exist custom
earli see trend due possibl upcom headwind
larger custom brand busi lower margin drop
also affect opioid cost
tax rate consolid global foot rate cordi brand price brand
cordi tax rate declin due restructur legal entiti outsid
cardin health brand price affect market suppli
price commod creat cost pressur expect continu
sever quarter reflect guidanc
cordi manufactur product slow reflect
guidanc need clarifi multipl time
guidanc enterpris level
perform line oper
downstream continu evalu price model price variou
product class appropri tri break bundl
appropri protect margin eros
upstream depend manufactur comfort wacc price
model like modifi conting price manufactur
inflat pressur commod high exact number
difficult due time issu
project year manag within guidanc
expos direct exposur product bought manufactur
well finish product sold ex glove
driver growth medic segment
exclud patient recoveri medic segment overal
servic busi grow forecast busi
aid medic segment growth perspect
cordi grown top line perspect past
quarter expect aid bottom line medic segment
busi futur
challeng commod suppli chain cost
biggest delta beyond make lower brand price inflat
alway season high
still expect amount brand inflat built
guidanc coupl percentag point absorb
ramp cost initi make price pressur
detail cost structur initi
target annual cost save
save goal comfort meet save
retain commit return cash sharehold plan continu
strateg flexibl invest busi opportun present
expect opioid cost exposur spread beyond ny state
cost due opioid litig fee ny state assess
major due legal fee
earli make comment expans state
review process assess busi process make sens
everyth tabl expens standpoint autom
aggress approach contract upstream downstream
pharmaceut medic segment
expect ebit flat
guidanc pharmaceut segment
strong revenu want extrapol
expect top-line heav healthi growth line guidanc
specialti strong expect continu strength throughout
year
still expect strong brand drug price see gener
deflat headwind throughout year
brand drug price pressur unit econom profit
activ engag manufactur regard unit rate
look compet stand-alone specialti pharmaci space
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
